Avid Bioservices Inc (NASDAQ: CDMO) closed the day trading at $7.74 down -3.13% from the previous closing price of $7.99. In other words, the price has decreased by -$0.25 from its previous closing price. On the day, 553928 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of CDMO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.85 and its Current Ratio is at 1.35. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 1.06.
On March 14, 2023, KeyBanc Capital Markets Upgraded its rating to Overweight which previously was Sector Weight but kept the price unchanged to $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 12 when Kwietniak Matthew R. sold 274 shares for $6.77 per share. The transaction valued at 1,855 led to the insider holds 19,829 shares of the business.
Hart Daniel R sold 2,408 shares of CDMO for $14,857 on Jan 10. The Chief Financial Officer now owns 79,305 shares after completing the transaction at $6.17 per share. On Jan 10, another insider, Ziebell Mark R, who serves as the V. P., General Counsel of the company, sold 1,346 shares for $6.17 each. As a result, the insider received 8,305 and left with 63,269 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDMO now has a Market Capitalization of 489.47M and an Enterprise Value of 653.34M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.47 while its Price-to-Book (P/B) ratio in mrq is 2.66. Its current Enterprise Value per Revenue stands at 4.64 whereas that against EBITDA is 1.08k.
Stock Price History:
The Beta on a monthly basis for CDMO is 1.66, which has changed by -52.72% over the last 52 weeks, in comparison to a change of 27.79% over the same period for the S&P500. Over the past 52 weeks, CDMO has reached a high of $21.05, while it has fallen to a 52-week low of $4.07. The 50-Day Moving Average of the stock is 6.60, while the 200-Day Moving Average is calculated to be 9.97.
Shares Statistics:
Over the past 3-months, CDMO traded about 1.52M shares per day on average, while over the past 10 days, CDMO traded about 967.67k shares per day. A total of 62.69M shares are outstanding, with a floating share count of 62.58M. Insiders hold about 1.05% of the company’s shares, while institutions hold 91.23% stake in the company. Shares short for CDMO as of Jan 31, 2024 were 5.23M with a Short Ratio of 3.45, compared to 5.65M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.27% and a Short% of Float of 9.87%.
Earnings Estimates
Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.07, while EPS last year was $0.01. The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.02 and low estimates of -$0.05.
Analysts are recommending an EPS of between -$0.23 and -$0.3 for the fiscal current year, implying an average EPS of -$0.26. EPS for the following year is -$0.03, with 4 analysts recommending between $0.03 and -$0.07.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for CDMO’s current fiscal year. The highest revenue estimate was $140.84M, while the lowest revenue estimate was $137M, resulting in an average revenue estimate of $138.9M. In the same quarter a year ago, actual revenue was $149.27M, down -6.90% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $166.31M in the next fiscal year. The high estimate is $175M and the low estimate is $160.01M. The average revenue growth estimate for next year is up 19.70% from the average revenue estimate for this year.
